Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Michael A. Spinner, MD, Marcelo Fernandez Vina, PhD, Linda Elder, BA, Sally Arai, MD, Laura Johnston, MD, Everett Meyer, MD PhD, David Miklos, MD PhD, Lori Muffly, MD, Robert S. Negrin, MD, Judith Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Samuel Strober, MD, Robert Lowsky, MD, Andrew R. Rezvani, MD

Blood (2016) 128 (22): 4669.

https://doi.org/10.1182/blood.V128.22.4669.4669

Published: 2016

Journal Articles

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Lori S. Muffly, MDMS, Kevin Sheehan, PhD, Randall Armstrong, Keri Tate, PhD, Cynthia Tudisco, Andrew R. Rezvani, MD, David Miklos, MD PhD, Sally Arai, MD, Judith Shizuru, MD PhD, Laura Johnston, Everett Meyer, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Robert S Negrin, MD, Sam Strober, Robert Lowsky, MD

Blood (2016) 128 (22): 4615.

https://doi.org/10.1182/blood.V128.22.4615.4615

Published: 2016

Journal Articles

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

Eileen P. Smith, MD, Hongli Li, M.S., Jonathan W. Friedberg, MD, Louis Constine, MD, Lisa M. Rimsza, MD, Ginna G. Laport, MD, Leslie L. Popplewell, MD, David G Maloney, MDPhD, Michael Leblanc, PhD, Stephen J. Forman, MD, Richard I. Fisher, MD, Patrick J. Stiff, MD

Blood (2014) 124 (21): 676.

https://doi.org/10.1182/blood.V124.21.676.676

Published: 2014

Journal Articles

Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)

Ginna G. Laport, MD, Juan Wu, MS, Brent R. Logan, PhD, Veronika Bachanova, MD, Chitra M. Hosing, Timothy S. Fenske, MD, Walter L. Longo, MD, Steven M. Devine, MD, Auayporn P. Nademanee, MDBS, Iris Gersten, MS, Mary M. Horowitz, MD MS, Hillard M. Lazarus, MD, Marcie L Riches, MD MS

Blood (2014) 124 (21): 682.

https://doi.org/10.1182/blood.V124.21.682.682

Published: 2014

Journal Articles

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Wen-Kai Weng, MD PhD, Randall Armstrong, Sally Arai, MD, Laura Johnston, MD, Ginna G. Laport, MD, Robert Lowsky, MD, David B. Miklos, Judith A. Shizuru, MD PhD, Jonathan E. Benjamin, Robert S. Negrin, MD, Sunil Reddy, MD, Lynn Million, MD, Richard T. Hoppe, MD, Youn H. Kim, MD

Blood (2014) 124 (21): 2544.

https://doi.org/10.1182/blood.V124.21.2544.2544

Published: 2014

Journal Articles

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

Christopher Bredeson, Jennifer LeRademacher, Kazunobu Kato, John F. DiPersio, Edward Agura, Steven M. Devine, Frederick R. Appelbaum, Marcie R. Tomblyn, Ginna G. Laport, Xiaochun Zhu, Philip L. McCarthy, Vincent T. Ho, Kenneth R. Cooke, Elizabeth Armstrong, Angela Smith, J. Douglas Rizzo, Jeanne M. Burkart, Marcelo C. Pasquini

Blood (2013) 122 (24): 3871–3878.

https://doi.org/10.1182/blood-2013-08-519009

Published: 2013

Includes: Supplemental data

Journal Articles

Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility

Jonathan Benjamin, MD, PhD, Ginna G Laport, MD, Keri Tate, PhD, Leah Galvez, RN, Randall Armstrong, Kevin Sheehan, PhD, Sally Arai, MD, Robert Lowsky, MD, Laura Johnston, MD, David B. Miklos, MD, PhD, Judith Shizuru, PhD, MD, Wen-Kai Weng, MD, PhD, Robert Negrin, MD

Blood (2013) 122 (21): 899.

https://doi.org/10.1182/blood.V122.21.899.899

Published: 2013

Journal Articles

Alternative Donor Transplantation For Adults With Lymphoma: Comparison Of Umbilical Cord Blood Versus 8/8 HLA-Matched Donor (URD) Versus 7/8 URD

Veronika Bachanova, MD, Claudio Brunstein, MD, Linda J. Burns, MD, Tao Wang, PhD, Jeanette Carreras, MPH, Ginna G. Laport, MD, Sonali M. Smith, MD, Silvia Montoto, MD, David G. Maloney, MD, PhD, Wael Saber, MD, MS

Blood (2013) 122 (21): 161.

https://doi.org/10.1182/blood.V122.21.161.161

Published: 2013

Journal Articles

Significant and Rapid Improvement in Survival After Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT): Analysis of National Marrow Donor Program (NMDP) Facilitated Transplants From 2000 to 2009

Blood (2012) 120 (21): 234.

https://doi.org/10.1182/blood.V120.21.234.234

Published: 2012

Journal Articles

Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.

Jonathan Benjamin, MD, PhD, Saurabh Chhabra, MD, Holbrook E Kohrt, MD, PhD, Ginna G Laport, MD, Sally Arai, MD, Laura Johnston, MD, David B Miklos, MD, PhD, Judith A. Shizuru, MD, PhD, Wen-Kai Weng, MD, PhD, Robert S. Negrin, MD, Robert Lowsky, MD

Blood (2012) 120 (21): 3087.

https://doi.org/10.1182/blood.V120.21.3087.3087

Published: 2012

Journal Articles

Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A Cibmtr Analysis

Mehdi Hamadani, MD, Wael Saber, MD, MS, Jeanette Carreras, MPH, Kwang W. Ahn, PhD, Ginna G. Laport, MD, Silvia Montoto, MD, David G. Maloney, MD, PhD, Hillard M. Lazarus, MD

Blood (2012) 120 (21): 473.

https://doi.org/10.1182/blood.V120.21.473.473

Published: 2012

Journal Articles

Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis

Mehdi Hamadani, MD, Wael Saber, MD, MS, Jeanette Carreras, MPH, Kwang W Ahn, PhD, Ginna G Laport, MD, Silvia Montoto, MD, David G. Maloney, MD, PhD, Hillard M Lazarus, MD

Blood (2012) 120 (21): 815.

https://doi.org/10.1182/blood.V120.21.815.815

Published: 2012

Journal Articles

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Frederick L Locke, MD, Joseph Pidala, MD, MS, Barry Storer, PhD, Paul J. Martin, MD, Michael A Pulsipher, MD, Thomas Chauncey, MD, PhD, Niels Jacobsen, MD, DMSC, Nikolaus Kroeger, MD, Irwin Walker, MBBS, Mary C Territo, Susan Light, MD, Ginna G Laport, MD, Auayporn Nademanee, MD, Raymond Powles, MD, Armand Keating, MD, Gerard Socie, MD, Claudio Anasetti, MD

Blood (2012) 120 (21): 4195.

https://doi.org/10.1182/blood.V120.21.4195.4195

Published: 2012

Journal Articles

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Blood (2012) 120 (20): 4256–4262.

https://doi.org/10.1182/blood-2012-06-436725

Published: 2012

Includes: Supplemental data

Journal Articles

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Sally Arai, Bita Sahaf, Balasubramanian Narasimhan, George L. Chen, Carol D. Jones, Robert Lowsky, Judith A. Shizuru, Laura J. Johnston, Ginna G. Laport, Wen-Kai Weng, Jonathan E. Benjamin, Joanna Schaenman, Janice Brown, Jessica Ramirez, James L. Zehnder, Robert S. Negrin, David B. Miklos

Blood (2012) 119 (25): 6145–6154.

https://doi.org/10.1182/blood-2011-12-395970

Published: 2012

Includes: Supplemental data

Journal Articles

Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL)

Ulrike Bacher, MD, Evgeny Klyuchnikov, MD, Jeanette Carreras, MPH, Jennifer Le-Rademacher, PhD, Ginna G. Laport, MD, Silvia Montoto, MD, David G. Maloney, MD, PhD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 501.

https://doi.org/10.1182/blood.V118.21.501.501

Published: 2011

Journal Articles

A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL)

Theresa Hahn, PhD, Philip L. McCarthy, Jr., MD, Jeanette Carreras, MPH, Mei-Jie Zhang, PhD, Hillard M. Lazarus, MD FACP, Ginna G. Laport, MD, Silvia Montoto, MD, David G. Maloney, MD, PhD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 499.

https://doi.org/10.1182/blood.V118.21.499.499

Published: 2011

Journal Articles

Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM)

Parameswaran Hari, MBBS, MD, MRCP, Marcelo C Pasquini, MD, MS, Brent R. Logan, PhD, Edward A. Stadtmauer, MD, Amrita Krishnan, MD, Alan Howard, PhD, Sairah Alvi, PhD, Stephen Harding, Shelly L Carter, ScD, Vincent Rajkumar, MD, Edwin P Alyea, III, MD, Muzaffar Qazilbash, MD, Ginna G. Laport, MD, David G. Maloney, MD, PhD, Sergio Giralt, MD, David H. Vesole, MD, PhD

Blood (2011) 118 (21): 2877.

https://doi.org/10.1182/blood.V118.21.2877.2877

Published: 2011

Journal Articles

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Leanthe Braunert, MD, Ginna G. Laport, MD, Thomas Chauncey, MD, Christopher Bredeson, Richard T Maziarz, MD, Michael A. Pulsipher, MD, Edward Agura, MD, Michael T. Maris, MD, Lars Vindelov, MD, Firoozeh Sahebi, M.D., Peter McSweeney, Benedetto Bruno, MD, Amelia Langston, MD, Rainer F. Storb, MD, David G. Maloney

Blood (2010) 116 (21): 2364.

https://doi.org/10.1182/blood.V116.21.2364.2364

Published: 2010

Journal Articles

The Role of Hematopoietic Cell Transplantation (HCT) for Burkitt Lymphoma: a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)

James L. Gajewski, MD, Jeanette Carreras, MPH, Hillard M. Lazarus, MD, FACP, Ginna G. Laport, MD, Silvia Montoto, MD, David G. Maloney, Parameswaran Hari, MD

Blood (2010) 116 (21): 2390.

https://doi.org/10.1182/blood.V116.21.2390.2390

Published: 2010

NARROW

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility

Alternative Donor Transplantation For Adults With Lymphoma: Comparison Of Umbilical Cord Blood Versus 8/8 HLA-Matched Donor (URD) Versus 7/8 URD

Significant and Rapid Improvement in Survival After Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT): Analysis of National Marrow Donor Program (NMDP) Facilitated Transplants From 2000 to 2009

Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.

Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A Cibmtr Analysis

Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL)

A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL)

Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM)

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

The Role of Hematopoietic Cell Transplantation (HCT) for Burkitt Lymphoma: a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only